Abcuro raised $66 million to restart development in inclusion body myositis, a rare inflammatory disorder with no approved therapies. The company plans to use the capital to run a Phase 2/3 study intended to support a biologics license application, after an earlier Phase 2/3 effort failed earlier this year. Abcuro said the new trial will build on positive trends observed in patients with less severe disease, aiming to refine the treatment population and reduce the risk of repeating a broad negative readout. The financing underscores investor appetite for late-stage rare-disease repositioning when prior signals exist, even after a setback. It also puts renewed focus on how patient stratification can determine whether biologics succeed in heterogeneous clinical phenotypes.